T cell engager

Immunocore's KIMMTRAK doubled five-year survival in metastatic uveal melanoma, achieving 16% vs. 8% control rate—longest T cell engager follow-up in solid tumors.

Boehringer Ingelheim and Zai Lab collaborate on Phase Ib/II study combining T-cell engager obrixtamig with ADC zocilurtatug for small cell lung cancer treatment.

Galapagos and Gilead form binding collaboration on gamgertamig, an autoimmune T cell engager, with Galapagos receiving 50% of Gilead's $1.675B Ouro Medicines acquisition.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.